Zeria Pharmaceutical is focused on advancing its research and development (R&D) capabilities, particularly in the gastrointestinal field. The company has established a robust pipeline of new drug candidates, including Acofide, a first-in-class therapeutic agent for functional dyspepsia. Zeria actively engages in global clinical trials and collaborates with international partners, such as Tillotts Pharma, to enhance its product offerings. Tillotts Pharma specializes in treatments for lower gastrointestinal tract conditions and is involved in developing improved formulations of existing drugs, thereby increasing their therapeutic value.

In addition to its pharmaceutical endeavors, Zeria is committed to developing consumer healthcare products that cater to diverse customer needs. This includes over-the-counter (OTC) medications, quasi-drugs, cosmetics, health foods, and medical devices aimed at promoting healthier lifestyles. The company’s strategic focus on both ethical pharmaceuticals and consumer healthcare reflects its dedication to providing effective treatments and products that support patient well-being and self-medication. Through efficient management of its R&D resources, Zeria aims to expedite the delivery of innovative therapies to patients worldwide.

Japan

At Zeria,our business is based on a set of guiding principles
we call the Z・E・R・I・A　Five Corporate Spirits.

Zoom in on healthcare
Excel in quality at every level
Reach out to the world
Inspire confidence in management
Achieve our potential

Zeria Pharmaceutical

Company Details